Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Sarilumab vs Tocilizumab in Japanese RA Patients
NCT02404558Phase 1Completed
- Sponsor
- Sanofi
- Start
- May 2015
- Primary completion
- Mar 2016
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sarilumab in rheumatoid arthritis (RA) (2 arms), sponsored by Sanofi. Primary endpoints: Percentage of patients with adverse events at 6 weeks, Percentage of patients with potentially clinically significant laboratory abnormalities at 6 weeks and 1 more. Started May 2015; status: completed.
02
Drugs
sarilumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02404558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02404558.